← Back to feed Tech & Digital

China AI drug-design deals swell as US scrutiny mounts

South China Morning Post / 02 July 2026 / 11h ago

Culture Index

Score Breakdown

Relevance

9/25

Freshness

25/25

Authority

18/20

Brand Signal

10/15

Depth

6/15

5-Axis Cultural Radar

Riding a wave of booming cross-border dealmaking, China’s AI-driven drug-design firms are charging onto the global stage despite Washington’s growing scrutiny of Chinese biotech firms. The value of out-licensing deals struck by Chinese biotech companies with top global multinational pharmaceutical companies climbed to US$75 billion in the first five months of 2026, up from zero before 2020, accord

Read Full Article → South China Morning Post ↗

China AI drug-design deals swell as US scrutiny mounts

More in Tech & Digital

Indian tech tycoon bets $30M of his own money to build AI alternative to Microsoft Office

Sources: Crusoe is in active talks to raise ~$3B in a funding round expected to value the company in the ~$30B range, up from a ~$10B valuation in October (Bloomberg)

Memo: Microsoft is merging the consumer and enterprise versions of its Copilot chatbots into a single app featuring coding tools and AI agents dubbed AutoPilot (The Information)